The role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 7032-7032 ◽  
Author(s):  
F. Li ◽  
G. y. Zhu ◽  
X. N. Li ◽  
R. Yu ◽  
A. Shi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Mutation Status

Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

2014 ◽  
Vol 41 (11) ◽  
pp. 2058-2065 ◽  
Author(s):  
Carlos Caicedo ◽  
Maria Jose Garcia-Velloso ◽  
Maria Dolores Lozano ◽  
Tania Labiano ◽  
Carmen Vigil Diaz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
18F Fdg

scholarly journals Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

2014 ◽  
Vol 41 (11) ◽  
pp. 2164-2164
Author(s):  
Carlos Caicedo ◽  
Maria Jose Garcia-Velloso ◽  
Maria Dolores Lozano ◽  
Tania Labiano ◽  
Carmen Vigil-Diaz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
18F Fdg

scholarly journals Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer

2020 ◽  
Vol 9 (12) ◽  
pp. 3881
Author(s):  
Shigeki Suzuki ◽  
Taichiro Goto
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Surgical Intervention ◽  
Salvage Surgery ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung

With the development of systemic treatments with high response rates, including tyrosine kinase inhibitors and immune checkpoint inhibitors, some patients with unresectable lung cancer now have a chance to undergo radical resection after primary treatment. Although there is no general consensus regarding the definition of “unresectable” in lung cancer, the term “resectable” refers to technically resectable and indicates that resection can provide a favorable prognosis to some extent. Unresectable lung cancer is typically represented by stage III and IV disease. Stage III lung cancer is a heterogeneous disease, and in some patients with technically resectable non-small cell lung cancer (NSCLC), multimodality treatments, including induction chemoradiotherapy followed by surgery, are the treatments of choice. The representative surgical intervention for unresectable stage III/IV NSCLC is salvage surgery, which refers to surgical treatment for local residual/recurrent lesions after definitive non-surgical treatment. Surgical intervention is also used for an oligometastatic stage IV NSCLC. In this review, we highlight the role of surgical intervention in patients with unresectable NSCLC, for whom an initial complete resection is technically difficult. We further describe the history of and new findings on salvage surgery for unresectable NSCLC and surgery for oligometastatic NSCLC.

scholarly journals ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting

2018 ◽  
Vol 10 (7) ◽  
pp. 4169-4177 ◽  
Author(s):  
Shirong Zhang ◽  
Lucheng Zhu ◽  
Xueqin Chen ◽  
Xiaochen Zhang ◽  
Enguo Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Real World Setting
Sign in / Sign up

Export Citation Format

Share Document